BGI Genomics Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 3,580

Employees

  • Stock Symbol
  • 300676

Stock Symbol

  • Investments
  • 40

  • Share Price
  • $5.16
  • (As of Thursday Closing)

BGI Genomics General Information

Description

BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.

Contact Information

Website
www.bgi.com
Formerly Known As
Cultural Revolution, Beijing Genome Institute
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • BGI Spacetime Center, No. 9 Yunhua Road
  • Meisha Street, Yantian District
  • Shenzhen, Guangdong 518083
  • China
+86 400
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Biotechnology
Stock Exchange
SHE
Corporate Office
  • BGI Spacetime Center, No. 9 Yunhua Road
  • Meisha Street, Yantian District
  • Shenzhen, Guangdong 518083
  • China
+86 400

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BGI Genomics Stock Performance

As of 19-Nov-2026, BGI Genomics’s stock price is $5.16. Its current market cap is $2.16B with 418M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.16 $5.22 $4.81 - $9.32 $2.16B 418M 10.8M -$0.19

BGI Genomics Financials Summary

As of 30-Sep-2026, BGI Genomics has a trailing 12-month revenue of $540M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,485,968 2,297,480 1,878,116 2,186,348
Revenue 540,272 515,258 538,909 614,800
EBITDA (76,288) (18,876) (66,377) 69,526
Net Income (79,070) (85,750) (125,803) 13,131
Total Assets 1,656,355 1,679,258 1,718,098 1,920,409
Total Debt 107,517 91,528 64,752 154,672
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BGI Genomics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BGI Genomics‘s full profile, request access.

Request a free trial

BGI Genomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and researc
Laboratory Services (Healthcare)
Shenzhen, China
3,580 As of 2025

Beijing, China
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BGI Genomics Competitors (23)

One of BGI Genomics’s 23 competitors is Novogene, a Formerly PE-Backed company based in Beijing, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novogene Formerly PE-Backed Beijing, China
Dante Labs Private Equity-Backed New York, NY
Genuity Science Formerly VC-backed Dublin, Ireland
Gene By Gene Formerly VC-backed Houston, TX
Agendia Venture Capital-Backed Irvine, CA
You’re viewing 5 of 23 competitors. Get the full list »

BGI Genomics Patents

BGI Genomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026227447-A1 Method for enrichment of enzymatic digestion product, library construction method, and use thereof Pending 30-Apr-2025
WO-2026227325-A1 Primer set and kit for detecting smn1 and smn2 gene mutations and use thereof Pending 29-Apr-2025
WO-2026227340-A1 Primer set for detecting number of cgg repeats and agg interruptions in fmr1 gene, and use thereof Pending 29-Apr-2025
WO-2026227347-A1 Primer set, kit and method for detecting cyp21a2 gene mutation Pending 29-Apr-2025
WO-2026152464-A1 Multi-omics detection method for plasma cfdna and use thereof Pending 20-Jan-2025
To view BGI Genomics’s complete patent history, request access »

BGI Genomics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BGI Genomics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BGI Genomics‘s full profile, request access.

Request a free trial

BGI Genomics Investments & Acquisitions (40)

BGI Genomics’s most recent deal was a Joint Venture with Xingtai Gene. The deal was made on 16-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Xingtai Gene 16-Dec-2025 Joint Venture Laboratory Services (Healthcare)
Geneplus Technology 31-Jul-2025 Secondary Transaction - Private Laboratory Services (Healthcare)
HyperSilicon 26-Mar-2024 Later Stage VC General Purpose Semiconductors
Genolmmune Therapeutics 28-Dec-2022 Later Stage VC Drug Discovery
Bamble AI Training 14-Dec-2022 Accelerator/Incubator Business/Productivity Software
You’re viewing 5 of 40 investments and acquisitions. Get the full list »

BGI Genomics ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

20.57 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 67

Rank

Percentile

To view BGI Genomics’s complete esg history, request access »

BGI Genomics Exits (6)

BGI Genomics’s most recent exit was on 30-Apr-2019 from Congenica. The exit was categorized as with 9 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Congenica 30-Apr-2019 Completed
  • 9 buyers
Baidao Medical 10-Dec-2018 Completed
  • 2 buyers
He's Eye Hospital 07-Dec-2017 Completed
  • 2 buyers
He's Eye Hospital 07-Dec-2017 Completed
  • 2 buyers
Gendi Healthcare 23-Jun-2016 Seed Round Completed
You’re viewing 5 of 6 exits. Get the full list »

BGI Genomics Affiliates

Subsidiaries (7)

Name Industry Location Year Founded
Huada GreenPine Angel Fund Shenzhen, China 2021
Hemu Gene Biotechnology Shenzhen, China 2018
Genolmmune Therapeutics Wuhan, China 2017
MGI Tech Shenzhen, China 2016
Miracle Light Venture Shenzhen, China 2016
You’re viewing 5 of 7 affiliates. Get the full list.  »

BGI Genomics FAQs

  • When was BGI Genomics founded?

    BGI Genomics was founded in 1999.

  • Where is BGI Genomics headquartered?

    BGI Genomics is headquartered in Shenzhen, China.

  • What is the size of BGI Genomics?

    BGI Genomics has 3,580 total employees.

  • What industry is BGI Genomics in?

    BGI Genomics’s primary industry is Laboratory Services (Healthcare).

  • Is BGI Genomics a private or public company?

    BGI Genomics is a Public company.

  • What is BGI Genomics’s stock symbol?

    The ticker symbol for BGI Genomics is 300676.

  • What is the current stock price of BGI Genomics?

    As of 19-Nov-2026 the stock price of BGI Genomics is $5.16.

  • What is the current market cap of BGI Genomics?

    The current market capitalization of BGI Genomics is $2.16B.

  • What is BGI Genomics’s current revenue?

    The trailing twelve month revenue for BGI Genomics is $540M.

  • Who are BGI Genomics’s competitors?

    Novogene, Dante Labs, Genuity Science, Gene By Gene, and Agendia are some of the 23 competitors of BGI Genomics.

  • What is BGI Genomics’s annual earnings per share (EPS)?

    BGI Genomics’s EPS for 12 months was -$0.19.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process